Vor Biopharma

Vor Biopharma: Series C Funding Round

Vor Biopharma has successfully raised $110M in Series C funding, reaching a valuation of $700M.

Company Overview

Engineering hematopoietic stem cells

Funding Details

The Series C round was led by 5AM Ventures, with participation from Fidelity, SR One, Novartis Venture Fund, Cormorant Asset Management.

Company Information

• Headquarters: 200 Sidney Street, Cambridge, MA 02139
• Founded: 2015
• Employees: 150+
• Category: Biotech

Investment

Vor Biopharma plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

• 5AM Ventures: Verified investor in Series C
• Fidelity: Verified investor in Series C
• SR One: Verified investor in Series C
• Novartis Venture Fund: Verified investor in Series C
• Cormorant Asset Management: Verified investor in Series C